Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

Questions Over Phase I Adverse Event

Executive Summary

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

You may also be interested in...



J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21

Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year. 

Adverse Reactions To Pfizer Vaccine Weaken Case For India Trial Waiver

Indian regulator is likely to ask Pfizer/BioNTech to conduct clinical trials before granting an accelerated approval, but recruitment could prove challenging for the COVID-19 vaccine as anaphylactic reactions in the US and UK sparks worry.

Questions India Faces As It Readies COVID-19 Vaccinations

Which vaccines will India use for immunizing its 1.35 billion population against COVID-19? Where will the money come from? Will it allow sales of these vaccines in the market? As the world’s largest democracy gets set to roll out its immunization plan, here’s a look at a few pertinent questions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel